Omeros Corporation

Equities

OMER

US6821431029

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
3.42 USD -1.16% Intraday chart for Omeros Corporation -9.28% +4.59%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Tech in Focus on -2- DJ
North American Morning Briefing : Investors -2- DJ
National Bank Raises DRI Healthcare Target to $22 on Omidria News, Guidance Increase MT
DRI Healthcare Trust Expands Royalty Entitlement on US Net Sales of Omidria, Updates Deployment and CAGR Guidance MT
Omeros Corporation(NasdaqGM:OMER) dropped from NASDAQ Biotechnology Index CI
North American Morning Briefing : Stock Futures -2- DJ
Transcript : Omeros Corporation, Q3 2023 Earnings Call, Nov 09, 2023
Omeros Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting CI
Novartis drug candidate scores interim win in rare kidney disease trial RE
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer CI
US Equity Markets Close Higher Monday on Expectations for Upbeat Q3 Earnings MT
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care MT
Top Midday Decliners MT
Omeros to Discontinue Phase 3 Trial of Narsoplimab After Failing to Reach Statistical Significance in Reducing Proteinuria MT
Transcript : Omeros Corporation - Special Call
Omeros to shut kidney disease trial as therapy fails in late-stage study RE
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy CI
Omeros Shares Jumped in After-Market Wednesday as CEO, General Counsel, Chief Accounting Officer Receive Stock Options MT
Transcript : Omeros Corporation, Q2 2023 Earnings Call, Aug 09, 2023
Omeros Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Omeros Corporation(NasdaqGM:OMER) added to Russell Small Cap Comp Value Index CI
Omeros Corporation(NasdaqGM:OMER) added to Russell 3000E Growth Index CI
Omeros Corporation(NasdaqGM:OMER) added to Russell Small Cap Completeness Index CI
Chart Omeros Corporation
More charts
Omeros Corporation is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria, complement 3 (C3) glomerulopathy and one or more related indications.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
3.42
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock Omeros Corporation - Nasdaq
  4. News Omeros Corporation
  5. Omeros : Unveils Initial Results From Narsoplimab Treatment of Additional 'Critically Ill' COVID-19 Patients